Document:

Warrant
Agreement

 

Dated
as of February 28, 2018

 

 

 

    	 	 	 

     

    

 

WARRANT
AGREEMENT, (this “Agreement”) dated as of February 28, 2018, by AgeX Therapeutics, Inc., a Delaware corporation (the
“Company”), for the benefit of each registered holder of a Warrant described herein (a “Holder”).

 

Section
1. Issuance of Warrants.

 

1.1
Number of Warrants. The Company is issuing to the original Holders named on Schedule 1 Warrants to purchase up to an aggregate
of 2,000,000 shares of Company Common Stock (“Warrant Shares”).

 

1.2
Expiration Date. The right to exercise the Warrants shall expire on, and the Warrants may not be exercised after, the Expiration
Date. The Expiration Date shall be the earliest to occur of (a) 5:00 p.m. New York time on February 28, 2021, (b) 5:00
p.m. New York time on the date specified as the Expiration Date in a notice from the Company to each Warrant holder given after
the “VWAP” of the Common Stock has exceeded $3.75 with an average trading volume greater than 50,000 shares for a
period of 20 Trading Days out of 30 consecutive Trading Days, provided that the Expiration Date shall not be earlier than ten
(10) Business Days after the date such notice is given to the Warrant holders and shall not occur earlier than January 31, 2019,
and (c) 5:00 p.m. New York time on the date on which a Change of Control occurs.

 

1.3
Form of Warrant. The text of the Warrants and of the Purchase Form shall be substantially as set forth in Exhibit A attached
hereto.

 

1.4
Signatures; Date of Warrants. The Warrants shall be executed on behalf of the Company by its Chief Executive Officer and
attested by its Chief Financial Officer or Secretary or any Assistant Secretary. The signature of any such officers on the Warrants
may be manual or facsimile. Warrants bearing the manual or facsimile signatures of individuals who were at any time the proper
officers of the Company shall bind the Company, notwithstanding that such individuals or any one of them shall have ceased to
hold such offices prior to the delivery of such Warrants or did not hold such offices on the date of this Agreement. In the event
that the Company shall appoint a warrant agent to act on its behalf in connection with the division, transfer, exchange or exercise
of Warrants, the Warrants issued after the date of such appointment shall be dated as of the date of countersignature thereof
by the warrant agent upon division, exchange, substitution or transfer. Until such time as the Company shall appoint a warrant
agent, Warrants shall be dated as of the date of execution thereof by the Company either upon initial issuance or upon division,
exchange, substitution or transfer.

 

1.5
Countersignature of Warrants. In the event that the Company shall appoint a warrant agent to act on its behalf in connection
with the division, transfer, exchange or exercise of Warrants, the Warrants issued after the date of such appointment shall be
countersigned by the warrant agent (or any successor to the warrant agent then acting as warrant agent) and shall not be valid
for any purpose unless so countersigned. Warrants may be countersigned, however, by the warrant agent (or by its successor as
warrant agent hereunder) and may be delivered by the warrant agent, notwithstanding that the persons whose manual or facsimile
signatures appear thereon as proper officers of the Company shall have ceased to be such officers at the time of such countersignature,
issuance or delivery. The warrant agent (if so appointed) shall, upon written instructions of the Chief Executive Officer or the
Chief Financial Officer of the Company, countersign, issue and deliver the Warrants as provided in this Agreement.

 

    	 	1	 

     

    

 

Section
2. Warrant Price. Subject to any adjustments required by Section 6, the price per share at which Warrant Shares shall be
purchasable upon exercise of a Warrant (as to any particular Warrant, the “Warrant Price”) shall be Two Dollars and
Fifty Cents ($2.50) per share.

 

Section
3. Exercise of Warrants; Restrictions.

 

3.1
Exercise of Warrants. Subject to the terms of this Agreement, a Holder of a Warrant (including any Warrants into which
a Warrant may be divided) shall have the right, which may be exercised, in whole or in part, to purchase from the Company, at
the Warrant Price then in effect, the number of fully paid and nonassessable Warrant Shares determined as provided in this Agreement.
The Warrants may not be exercised or transferred after the Expiration Date. A Warrant may be exercised by (i) surrender of the
certificate evidencing the Warrant to be exercised, together with the form of election to purchase on the reverse thereof duly
completed and signed, to the Company at its principal office (or if appointed, the principal office of the warrant agent) and
(ii) payment of the Warrant Price to the Company (or if appointed, to the warrant agent for the account of the Company), for the
number of Warrant Shares in respect of which the Warrant is then being exercised. Payment of the aggregate Warrant Price shall
be made by bank wire transfer to the account of the Company or by bank cashier’s check.

 

3.2
Periods During Warrants May Be Exercised. If the Company’s Common Stock (or other class or series of securities comprising
the Warrant Shares) is listed or traded on an Eligible Market, the Warrants may be exercised at any time on or before the Expiration
Date. If the Company’s Common Stock (or other class or series of securities comprising the Warrant Shares) is not listed
or traded on an Eligible Market, the Warrants may be exercised only during the period commencing ten (10) Business Days prior
to the Expiration Date and ending on the Expiration Date,

 

3.3
Issuance of Warrant Shares. Subject to Section 3.2, Section 3.4, and Section 5, following the surrender of the Warrant
with the form of election to purchase on the reverse thereof duly completed and signed, and provided that payment of the Warrant
Price has been received, the Company (or if appointed, the warrant agent) shall promptly cause to be issued and delivered to or
upon the written order of the Holder and in such name or names as the Holder may designate, a certificate or certificates for
the number of full Warrant Shares so purchased upon the exercise of such Warrant, together with cash, as provided in Section 8,
in respect of any fractional Warrant Shares otherwise issuable upon such exercise. Such Warrant Share certificate or certificates
shall be deemed to have been issued and any person so designated to be named therein shall be deemed to have become a holder of
record of such Warrant Shares as of the date on which the Warrant with the form of election to purchase on the reverse thereof
duly completed and signed and payment of the Warrant Price, as aforesaid, shall have been received by the Company (or if appointed,
to the warrant agent for the account of the Company), for such Warrant Shares. In the event that a certificate evidencing the
Warrant is exercised in respect of less than all of the Warrant Shares purchasable on such exercise at any time prior to the tenth
Business Day prior to the Expiration Date, a new certificate evidencing the unexercised portion of the Warrant will be issued,
and the warrant agent (if so appointed) is hereby irrevocably authorized to countersign and to deliver the required new Warrant
certificate or certificates. The Company, whenever required by the warrant agent (if appointed), will supply the warrant agent
with Warrant certificates duly executed on behalf of the Company for such purpose.

 

    	 	2	 

     

    

 

3.4
Restrictions on Exercise of Warrants.

 

(a)
The Warrants may not be exercised unless registered under the Securities Act or an exemption from such registration is available.

 

(b)
Unless the Warrant and Warrant Shares have been registered under the Securities Act and under any applicable state securities
laws, each Person who is exercising a Warrant will be required to give written certification that such Person is an “accredited
investor” or a written opinion of counsel, acceptable to the Company and to the transfer agent of the Warrant Shares, to
the effect that exercise of the Warrant and the issuance of the Warrant Shares are exempt from registration under the Securities
Act and under any applicable state securities laws.

 

(c)
The Company shall be entitled to obtain, as a condition precedent to its issuance of any certificates representing Warrant Shares
or any other securities issuable upon any exercise of a Warrant, a letter or other instrument from the Holder containing such
covenants, representations or warranties by such Holder as reasonably deemed necessary by the Company to effect compliance by
the Company with the requirements of the Securities Act and any other applicable United States federal and/or state securities
laws.

 

(d)
Any exercise, attempt to exercise, or purported exercise of a Warrant in violation of the restrictions set forth in this Section
3.4 shall be deemed null and void and of no binding effect.

 

(e)
The Company will refuse to issue, and will issue instructions to the transfer agent and registrar of its Warrant Shares to refuse
to issue, any Warrant Shares upon any exercise not made pursuant to registration under the Securities Act and applicable state
securities laws, or pursuant to an available exemption from registration under the Securities Act and applicable state securities
laws.

 

Section
4. Transferability of Warrants and Warrant Shares; Restrictions on Transfer.

 

4.1
Registration. Each Warrant shall be numbered and shall be registered on the books of the Company (the “Warrant Register”)
as issued. The Company and the warrant agent (if appointed) shall be entitled to treat the Holder of any Warrant appearing in
the Warrant Register as the owner in fact of the Warrant for all purposes and shall not be bound to recognize any equitable or
other claim or interest in the Warrant on the part of any other person, and shall not be liable for any registration of transfer
of any Warrant which is registered or to be registered in the name of a fiduciary or the nominee of a fiduciary upon the instruction
of such fiduciary, unless made with the actual knowledge that a fiduciary or nominee is committing a breach of trust in requesting
such registration of transfer, or with such knowledge of such facts that its participation therein amounts to bad faith. Each
Warrant shall initially be registered in the name of the Person to whom it is originally issued.

 

    	 	3	 

     

    

 

4.2
Transfer. Subject to Section 4.3, the Warrants shall be transferable only on the Warrant Register upon delivery of the
Warrant certificate duly endorsed by the Holder or by the Holder’s duly authorized attorney or representative, or accompanied
by proper evidence of succession, assignment or authority to transfer. In all cases of transfer by an attorney, the original power
of attorney or a duly certified copy thereof shall be deposited and remain with the Company (or the warrant agent, if appointed).
In case of transfer by executors, administrators, guardians or other legal representatives, duly authenticated evidence of their
authority shall be produced, and may be required to be deposited and remain with the Company (or the warrant agent, if appointed)
in its discretion. Upon any registration of transfer, the Company shall execute and deliver (or if appointed, the warrant agent
shall countersign and deliver) a new Warrant or Warrants to the Persons entitled thereto.

 

4.3
Restrictions on Transfer of Warrants and Warrant Shares.

 

(a)
The Warrants, and any Warrant Shares issued upon the exercise of the Warrants, may not be sold, pledged, hypothecated, transferred
or assigned, in whole or in part, unless a registration statement under the Securities Act, and under any applicable state securities
laws, is effective therefor, or an exemption from such registration is then available and an opinion of counsel, acceptable to
the Company and to the transfer agent or warrant agent, if any, has been rendered stating that such sale, pledge, hypothecation,
transfer or assignment will not violate the Securities Act or any other United States federal or state securities laws.

 

(b)
As a condition precedent to the registration of transfer and issuance of any certificates representing Warrants or Warrant Shares
upon transfer, the Company shall be entitled to obtain a letter or other instrument from the Holder containing such covenants,
representations or warranties by such Holder as reasonably deemed necessary by the Company to effect compliance by the Company
with the requirements of the Securities Act and any other applicable federal and/or state securities laws.

 

(c)
Any sale, pledge, hypothecation, transfer, or assignment of a Warrant or Warrant Shares in violation of the foregoing restrictions
shall be deemed null and void and of no binding effect.

 

(d)
The Company will issue instructions to any warrant agent that may be appointed, and to the transfer agent and registrar of its
Warrant Shares, to refuse to register the transfer of any Warrant and Warrant Shares not made pursuant to registration under the
Securities Act and applicable state securities laws, or pursuant to an available exemption from registration under the Securities
Act and applicable state securities laws.

 

    	 	4	 

     

    

 

Section
5. Payment of Taxes. The Company will pay all documentary stamp taxes, if any, attributable to the initial issuance of
Warrant Shares upon the exercise of Warrants; provided, however, that the Company shall not be required to pay any tax or taxes
which may be payable in respect of any transfer involved in the issue or delivery of any Warrant or certificates for Warrant Shares
in a name other than that of the registered Holder of such Warrants or Warrant Shares.

 

Section
6. Adjustment of Warrant Price and Number of Warrant Shares. The number and kind of securities purchasable upon the exercise
of each Warrant and the Warrant Price shall be subject to adjustment from time to time upon the happening of certain events, as
provided in this Section 6.

 

6.1
Adjustments. The number of Warrant Shares purchasable upon the exercise of each Warrant and the Warrant Price shall be
subject to adjustment as follows:

 

(a)
If the Company shall (i) pay a dividend in shares of Common Stock or make a distribution in shares of Common Stock, (ii) subdivide
its outstanding shares of Common Stock, (iii) combine its outstanding shares of Common Stock into a smaller number of shares of
Common Stock or (iv) reclassify or change its Common Stock (including any such reclassification or change in connection with a
consolidation or merger in which the Company is the surviving corporation), the number of Warrant Shares purchasable upon exercise
of each Warrant immediately prior thereto shall be adjusted so that the Holder of each Warrant shall be entitled to receive the
kind and number of Warrant Shares or other securities of the Company or other property which the Holder would have owned or have
been entitled to receive after the happening of any of the events described above, had such Warrant been exercised immediately
prior to the happening of such event or any record date with respect thereto. An adjustment made pursuant to this paragraph (a)
shall become effective immediately after the effective date of such event retroactive to the record date, if any, for such event.

 

(b)
If the Company shall issue rights, options or warrants to all holders of its outstanding Common Stock, without any charge to such
holders, entitling them to subscribe for or purchase shares of Common Stock at a price per share which is lower at the record
date mentioned below than the then current market price per share of Common Stock, the number of Warrant Shares thereafter purchasable
upon the exercise of each Warrant shall be determined by multiplying the number of Warrant Shares theretofore purchasable upon
exercise of each Warrant by a fraction, of which the numerator shall be the number of shares of Common Stock outstanding on the
date of issuance of such rights, options or warrants plus the number of additional shares of Common Stock offered for subscription
or purchase in connection with such rights, options or warrants, and of which the denominator shall be the number of shares of
Common Stock outstanding on the date of issuance of such rights, options or warrants plus the number of shares which the aggregate
exercise price for the total number of shares of Common Stock issuable upon exercise of such rights, options or warrants would
purchase at the current market price per share of Common Stock (as determined pursuant to paragraph (d) below) at such record
date. Such adjustment shall be made whenever such rights, options or warrants are issued, and shall become effective immediately
after the record date for the determination of stockholders entitled to receive such rights, options or warrants.

 

    	 	5	 

     

    

 

(c)
If the Company shall distribute to all holders of its shares of Common Stock (including any distribution made in connection with
a merger in which the Company is the surviving corporation) evidences of its indebtedness or assets (excluding cash, dividends
or distributions payable out of consolidated earnings or earned surplus and dividends or distributions referred to in paragraph
(a) above) or rights, options or warrants, or convertible or exchangeable securities containing the right to subscribe for or
purchase shares of Common Stock (excluding those referred to in paragraph (b) above), then in each case the number of Warrant
Shares thereafter purchasable upon the exercise of each Warrant shall be determined by multiplying the number of Warrant Shares
theretofore purchasable upon the exercise of each Warrant by a fraction, of which the numerator shall be the then current market
price per share of Common Stock (as determined pursuant to paragraph (d) below) on the date of such distribution, and of which
the denominator shall be the then current market price per share of Common Stock, less the then fair value (as reasonably determined
by the Board of Directors of the Company, whose determination shall be conclusive) of the portion of the assets or evidences of
indebtedness so distributed or of such subscription rights, options or warrants, or of such convertible or exchangeable securities
applicable to one share of Common Stock. Such adjustment shall be made whenever any such distribution is made, and shall become
effective on the date of distribution retroactive to the record date for the determination of stockholders entitled to receive
such distribution.

 

(d)
For the purpose of any computation under paragraphs (b) and (c) of this Section 6.1, the current market price per share of Common
Stock at any date shall be the VWAP of the Common Stock for the 20 consecutive Trading Days ending one Trading Day prior to the
date of such computation. If the current market price of the Common Stock cannot be so determined, the Board of Directors of the
Company shall reasonably determine the fair market value of the Common Stock and such value shall be deemed the current market
price.

 

(e)
No adjustment in the number of Warrant Shares purchasable hereunder shall be required unless such adjustment would require an
increase or decrease of at least one percent (1%) in the number of Warrant Shares purchasable upon the exercise of each Warrant;
provided, however, that any adjustments which by reason of this paragraph (e) are not required to be made shall be carried forward
and taken into account in the determination of any subsequent adjustment. All calculations shall be made with respect to the number
of Warrant Shares purchasable hereunder, to the nearest tenth of a share and with respect to the Warrant Price payable hereunder,
to the nearest whole cent.

 

(f)
Whenever the number of Warrant Shares purchasable upon the exercise of each Warrant is adjusted, as herein provided, the Warrant
Price payable upon exercise of each Warrant shall be adjusted by multiplying such Warrant Price immediately prior to such adjustment
by a fraction, of which the numerator shall be the number of Warrant Shares purchasable upon the exercise of each Warrant immediately
prior to such adjustment, and of which the denominator shall be the number of Warrant Shares purchasable immediately thereafter.

 

(g)
No adjustment in the number of Warrant Shares purchasable upon the exercise of each Warrant need be made under paragraphs (b)
and (c) if the Company issues or distributes to each Holder of Warrants the rights options, warrants, or convertible or exchangeable
securities, or evidences of indebtedness or assets referred to in those paragraphs which each Holder of Warrants would have been
entitled to receive had the Warrants been exercised prior to the happening of such event or the record date with respect thereto.
No adjustment need be made for a change in the par value of the Warrant Shares.

 

    	 	6	 

     

    

 

(h)
Upon the expiration of any rights, options, warrants or conversion or exchange privileges that result in an adjustment pursuant
to this Section 6.1, if any thereof shall not have been exercised, the Warrant Price and the number of Warrant Shares purchasable
upon the exercise of each Warrant shall, upon such expiration, be readjusted and shall thereafter be such as it would have been
had it been originally adjusted (or had the original adjustment not been required, as the case may be) as if (A) the only shares
of Common Stock so issued were the shares of Common Stock, if any, actually issued or sold upon the exercise of such rights, options,
warrants or conversion or exchange rights and (B) such shares of Common Stock, if any, were issued or sold for the consideration
actually received by the Company upon such exercise plus the aggregate consideration, if any, actually received by the Company
for the issuance, sale or grant of all such rights, options, warrants or conversion or exchange rights whether or not exercised.

 

6.2
Notice of Adjustment. Whenever the number of Warrant Shares purchasable upon the exercise of each Warrant or the Warrant
Price of such Warrant Shares is adjusted, as herein provided, the Company shall, or in the event that a warrant agent is appointed,
the Company shall cause the warrant agent to, promptly and in any event within ten (10) days send to each Holder notice of such
adjustment or adjustments. Such notice shall set forth the number of Warrant Shares purchasable upon the exercise of each Warrant
and the Warrant Price after such adjustment, setting forth a brief statement of the facts requiring such adjustment and setting
forth the computation by which such adjustment was made.

 

6.3
No Adjustment for Dividends. Except as provided in Section 6.1, no adjustment in respect of any dividends shall be made
during the term of a Warrant or upon the exercise of a Warrant.

 

6.4
Preservation of Purchase Rights Upon Merger, Consolidation, etc. In case of any consolidation of the Company with or merger
of the Company into another corporation or in case of any sale, transfer or lease to another corporation of all or substantially
all the assets of the Company, other than a transaction constituting, resulting in, or giving effect to a Change of Control, the
Company or such successor or purchasing corporation, as the case may be, shall execute an agreement that each Holder shall have
the right thereafter, upon such Holder’s election, either (i) upon payment of the Warrant Price in effect immediately prior
to such action, to purchase upon exercise of each Warrant the kind and amount of shares and other securities and property (including
cash) which the Holder would have owned or have been entitled to receive after the happening of such consolidation, merger, sale,
transfer or lease had such Warrant been exercised immediately prior to such action (such shares and other securities and property
(including cash) being referred to as the “Sale Consideration”) or (ii) to receive, in cancellation of such Warrant
(and in lieu of paying the Warrant price and exercising such Warrant), the Sale Consideration less a portion thereof having a
fair market value (as reasonably determined by the Company) equal to the Warrant Price (it being understood that, if the Sale
Consideration consists of more than one type of shares, other securities or property, the amount of each type of shares, other
securities or property to be received shall be reduced proportionately); provided, however, that no adjustment in respect of dividends,
interest or other income on or from such shares or other securities and property shall be made during the term of a Warrant or
upon the exercise of a Warrant. The Company shall mail by first class mail, postage prepaid, to each Holder, notice of the execution
of any such agreement. Such agreement shall provide for adjustments, which shall be as nearly equivalent as may be practicable
to the adjustments provided for in this Section 6. The provisions of this paragraph shall similarly apply to successive consolidations,
mergers, sales, transfers or leases other than transactions constituting, resulting in, or giving effect to a Change of Control.
The warrant agent (if appointed) shall be under no duty or responsibility to determine the correctness of any provisions contained
in any such agreement relating to the kind or amount of shares of stock or other securities or property receivable upon exercise
of Warrants or with respect to the method employed and provided therein for any adjustments and shall be entitled to rely upon
the provisions contained in any such agreement.

 

    	 	7	 

     

    

 

6.5
Statement on Warrants. Irrespective of any adjustments in the Warrant Price or the number or kind of shares purchasable
upon the exercise of the Warrants, Warrants issued before or after such adjustment may continue to express the same price and
number and kind of shares as are stated in the Warrants initially issuable pursuant to this Agreement.

 

Section
7. Reservation of Warrant Shares; Purchase and Cancellation of Warrants.

 

7.1
Reservation of Warrant Shares. There have been reserved, and the Company shall at all times keep reserved, out of its authorized
Common Stock, a number of shares of Common Stock sufficient to provide for the exercise of the rights of purchase represented
by the outstanding Warrants. The Company will keep a copy of this Agreement on file with the transfer agent for the Warrant Shares.
The warrant agent, if appointed, will be irrevocably authorized to requisition from time to time from such transfer agent the
stock certificates required to honor outstanding Warrants upon exercise in accordance with the terms of this Agreement. The Company
will supply such transfer agent with duly executed stock certificates for such purposes and will provide or otherwise make available
any cash which may be payable as provided in Section 8. The Company will furnish such transfer agent a copy of all notices of
adjustments and certificates related thereto, transmitted to each Holder pursuant to Section 6.2.

 

7.2
Purchase of Warrants by the Company. The Company shall have the right, except as limited by law or by other agreements,
with the consent of the Holder, to purchase or otherwise acquire Warrants from the Holder at such times, in such manner and for
such consideration as it and the Holder may deem appropriate.

 

7.3
Cancellation of Warrants. In the event the Company shall purchase or otherwise acquire Warrants, the same shall thereupon
be cancelled and retired. The warrant agent (if so appointed) shall cancel any Warrant surrendered for exchange, substitution,
transfer or exercise in whole or in part.

 

Section
8. Fractional Interests. The Company shall not be required to issue fractional Warrants upon the transfer of any Warrant,
or fractional Warrant Shares upon the exercise of Warrants. If more than one Warrant shall be presented for exercise at the same
time by the same Holder, the number of full Warrant Shares which shall be issuable upon the exercise thereof shall be computed
on the basis of the aggregate number of Warrant Shares purchasable on exercise of the Warrants so presented. If any fraction of
a Warrant Share would, except for the provisions of this Section 8, be issuable on the exercise of any Warrant (or specified portion
thereof), the Company shall pay an amount in cash equal to the current market price per Warrant Share determined in accordance
with Section 6.1(d) as of one Trading Day prior to the date the Warrant is presented for exercise, multiplied by such fraction.

 

    	 	8	 

     

    

 

Section
9. Exchange of Warrant Certificates. Each Warrant certificate may be exchanged, at the option of the Holder thereof, for
another Warrant certificate or Warrant certificates in different denominations (but not for any fractional Warrant or any denomination
that would, but for Section 8, result in the issuance of a fractional share upon exercise) entitling the Holder or Holders thereof
to purchase a like aggregate number of Warrant Shares as the certificate or certificates surrendered then entitle the Holder to
purchase. Any Holder desiring to exchange a Warrant certificate or certificates shall make such request in writing delivered to
the Company at its principal office (or, if a warrant agent is appointed, the warrant agent at its principal office) and shall
surrender, properly endorsed, the certificate or certificates to be so exchanged. Thereupon, the Company (or, if appointed, the
warrant agent) shall execute and deliver to the person entitled thereto a new Warrant certificate or certificates, as the case
may be, as so requested, in such name or names as such Holder shall designate.

 

Section
10. Mutilated or Missing Warrants. In case any of the certificates evidencing the Warrants shall be mutilated, lost, stolen
or destroyed, the Company may in its discretion issue and deliver (and, if appointed, the warrant agent shall countersign and
deliver) in exchange and substitution for and upon cancellation of the mutilated Warrant certificate, or in lieu of and substitution
for the Warrant certificate lost, stolen or destroyed, a new Warrant certificate of like tenor, but only upon receipt of evidence
reasonably satisfactory to the Company and the warrant agent (if so appointed) of such loss, theft or destruction of such Warrant,
and an indemnity or bond, if requested, also reasonably satisfactory to them. An applicant for such a substitute Warrant certificate
shall also comply with such other reasonable requirements and pay such reasonable charges as the Company (or the warrant agent,
if so appointed) may prescribe.

 

Section
11. No Rights as Stockholders; Notices to Holders. Nothing contained in this Agreement or in any of the Warrants shall
be construed as conferring upon the Holders or their transferees the right to vote or to receive dividends or to consent or to
receive notice as stockholders in respect of any meeting of stockholders for the election of directors of the Company or any other
matter, or any rights whatsoever as stockholders of the Company. If, however, at any time prior to the Expiration Date if any
of the following events shall occur: (a) the Company shall declare any dividend payable in any securities upon its shares of Common
Stock or make any distribution (other than a regular cash dividend, as such dividend may be increased from time to time, or a
dividend payable in shares of Common Stock) to the holders of its shares of Common Stock; or (b) the Company shall distribute
rights, options or warrants to all holders of its outstanding Common Stock, without any charge to such holders, entitling them
to subscribe for or purchase shares of Common Stock or the Company shall otherwise offer to the holders of its shares of Common
Stock on a pro rata basis any cash, additional shares of Common Stock or other securities of the Company or any right to subscribe
for or purchase any thereof; (c) a consolidation, merger, sale, transfer or lease of all or substantially all of the Company’s
property, assets, and business as an entirety, or (d) a dissolution, liquidation or winding up of the Company, or (e) a transaction
between the Company and any other Person that will result in a Change of Control shall be proposed, then in any one or more of
said events the Company shall give notice in writing of such event as provided in Section 12, such giving of notice to be completed
at least 10 days prior to the date fixed as a record date or the date of closing the transfer books for the determination of the
stockholders entitled to such dividend or distribution or for the determination of stockholders entitled to vote on such proposed
merger, consolidation, sale of assets, dissolution, liquidation or winding up or the date on which a transaction to which the
Company is a party and which will cause or result in a Change of Control will be consummated. Such notice shall specify such record
date or the date of closing the transfer books, as the case may be. Failure to publish, mail or receive such notice or any defect
therein or in the publication or mailing thereof shall not affect the validity of any action in connection with such dividend,
distribution or subscription rights, or such proposed dissolution, liquidation or winding up.

 

    	 	9	 

     

    

 

Section
12. Notices; Principal Office. Any notice pursuant to this Agreement by the Company or by any Holder to the warrant agent
(if so appointed), or by the warrant agent (if so appointed) or by any Holder to the Company, shall be in writing and shall be
delivered in person, or mailed first class, postage prepaid, or sent by air delivery service (a) to the Company, at its office,
Attention: Chief Financial Officer, or (b) to the warrant agent, at its offices as designated at the time the warrant agent is
appointed. The address of the principal office of the Company is 1010 Atlantic Avenue, Suite 102, Alameda, California 94051. Any
notice given pursuant to this Agreement by the Company or the warrant agent to a Holder shall be in writing and shall be mailed
first class, postage prepaid, or sent by air delivery service, or delivered personally to such Holder at the Holder’s address
on the books of the Company or the warrant agent, as the case may be. A notice shall be deemed given on the date deposited in
the United States mail, first class postage prepaid, or on date deposited with an air delivery service, or on the date delivered
if personally delivered. The Company, the warrant agent (if appointed), and any Holder may from time to time change the address
to which notices to it are to be delivered or mailed hereunder by notice given as provided in this Section 12.

 

Section
13. Successors. Except as expressly provided herein to the contrary, all the covenants and provisions of this Agreement
by or for the benefit of the Company, the warrant agent (if appointed) and the Holder shall bind and inure to the benefit of their
respective successors and permitted assigns hereunder.

 

Section
14. Legends. The Warrants shall bear an appropriate legend, conspicuously disclosing the restrictions on exercise under
Section 3.4, and the Warrants and Warrant Shares shall bear an appropriate legend, conspicuously disclosing the restrictions on
transfer under Section 4.3 until the same are registered for sale under the Securities Act or are transferred in a transaction
exempt from registration under the Securities Act entitling the transferee to receive securities that are not deemed to be “restricted
securities” as such term is defined in Rule 144 under the Securities Act. The Company agrees that upon the sale of the Warrants
and Warrant Shares pursuant to a registration statement or an exemption entitling the transferee to receive securities that are
not deemed to be “restricted securities,” or at such time as registration under the Securities Act shall no longer
be required, upon the presentation of the certificates containing such a legend to the transfer agent or warrant agent, if any,
it will remove such legend; provided, that unless the request for removal of the legend is in connection with a sale registered
under the Securities Act, the Holder shall have provided an opinion of counsel, acceptable to the Company and the transfer agent
or warrant agent, as applicable, to the effect that such legend may be removed in compliance with the Securities Act.

 

    	 	10	 

     

    

 

Section
15. Applicable Law. This Agreement and each Warrant issued hereunder shall be governed by and construed in accordance with
the laws of the State of Delaware, without giving effect to principles of conflict of laws.

 

Section
16. Benefits of this Agreement. This Agreement shall be for the sole and exclusive benefit of the Company, the warrant
agent (if appointed), and the Holders. Nothing in this Agreement shall be construed to give to any Person other than the Company,
the warrant agent (if appointed), and the Holders any legal or equitable right, remedy or claim under this Agreement.

 

Section
17. Counterparts. This Agreement may be executed in any number of counterparts (including by separate counterpart signature
pages) and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together
constitute but one and the same instrument.

 

Section
18. Captions. The captions of the Sections and subsections of this Agreement have been inserted for convenience only and
shall have no substantive effect.

 

Section
19. Certain Definitions. For purposes of this Warrant Agreement and the Warrants, the following terms shall have the following
meanings:

 

19.1
“Common Stock” means the common stock, par value $0.0001 per share, of the Company and any other capital stock of
the Company issued in exchange therefor or into which such common stock may be converted through any reclassification or recapitalization
of such common stock of the Company; but excluding shares of any other Person into which Company common stock may be converted
or exchanged in connection with a merger or consolidation other than a merger or consolidation solely for the purpose of changing
the state of the Company’s incorporation.

 

19.2
“Company” means AgeX Therapeutics, Inc., a Delaware corporation.

 

19.3
“Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New
York are authorized or required by law to remain closed.

 

19.4
“Change of Control” means (a) a merger or consolidation of the Company with another Person other than (i) a merger
in which the Company is the surviving Person and the holders of Common Stock immediately before the merger hold more than 50%
of the Common Stock immediately after the merger or consolidation, or (ii) a merger solely for the purpose of changing the state
of the Company’s incorporation, (b) a tender offer or similar transaction through which a Person acquires more than 50%
of the outstanding Common Stock, or (c) a sale of all or substantially all of the assets of the Company.

 

    	 	11	 

     

    

 

19.5
“Expiration Date” shall have the meaning set forth in Section 1.2.

 

19.6
“Holder” means a registered holder of a Warrant as reflected on the Warrant Register.

 

19.7
“Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust,
an unincorporated organization, any other entity and a government or any department or agency thereof.

 

19.8
“Sale Consideration” shall have the meaning ascribed in Section 6.4

 

19.9
“Securities Act” means the Securities Act of 1933, as amended.

 

19.10
“Trading Day” means any day on which the Common Stock is traded on a securities exchange or market, provided
that “Trading Day” shall not include any day on which the Common Stock does not trade for at least 4.5 hours on at
least one exchange or securities market.

 

19.11
“VWAP” means volume-weighted average price per share.

 

19.12
“Warrants” mean the Common Stock purchase warrants issuable and governed pursuant to this Agreement.

 

19.13
“Warrant Price” shall have the meaning ascribed in Section 2.

 

19.14
“Warrant Register” shall have the meaning ascribed in Section 4.1.

 

19.15
“Warrant Share” shall have the meaning ascribed in Section 1.1.

 

    	 	12	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed, all as of the day and year first above written.

 

AGEX
THERAPEUTICS, INC.

 

	By:	/s/
    Michael     D. West 	 
	 	Michael
    D. West	 
	 	President
    and Chief Executive Officer	 

 

Attest:

 

	By:	/s/
    Russell Skibsted 	 
	 	Russell Skibsted,	 
	 	Chief Financial Officer	 

 

    	 	13	 

     

    

 

EXHIBIT
A

 

THIS
WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER APPLICABLE
STATE SECURITIES LAWS. THIS WARRANT MAY NOT BE EXERCISED, SOLD, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED EXCEPT PURSUANT
TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM REGISTRATION. HEDGING TRANSACTIONS INVOLVING THIS WARRANT OR ANY COMMON STOCK OR OTHER SECURITIES ISSUABLE UPON
EXERCISE OF THIS WARRANT MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT

 

VOID
AFTER 5:00 P.M. NEW YORK TIME ON THE EXPIRATION DATE

 

	Certificate
    No. ____	Warrant
    to Purchase
	 	 
	 	[Insert
    number of Shares]
	 	 
	 	Shares
    of Common Stock

 

AGEX
THERAPEUTICS, INC.

COMMON
STOCK PURCHASE WARRANTS

 

This
certifies that, for value received, _____________ or registered assigns (the “Holder”), is entitled to purchase from
AgeX Therapeutics, Inc., a Delaware corporation (the “Company”), at a purchase price per share of Two Dollars and
Fifty Cents ($2.50) (the “Warrant Price”), the number of shares of its Common Stock, par value $0.0001 per share (the
“Common Stock”), shown above. The series and number of shares purchasable upon exercise of the Common Stock Purchase
Warrants (the “Warrants”) and the Warrant Price are subject to adjustment from time to time as set forth in the Warrant
Agreement referred to below. Outstanding Warrants not exercised prior to 5:00 p.m., New York time, on the Expiration Date as defined
in the Warrant Agreement shall thereafter be void.

 

Subject
to restriction specified in the Warrant Agreement, Warrants may be exercised in whole or in part by presentation of this Warrant
Certificate with the Purchase Form on the reverse side hereof duly executed, and simultaneous payment of the Warrant Price (or
as otherwise set forth in Section 6.4 of the Warrant Agreement) at the principal office of the Company (or if a warrant agent
is appointed, at the principal office of the warrant agent). Payment of the Warrant Price shall be made by bank wire transfer
to the account of the Company or by bank cashier’s check as provided in Section 3.1 of the Warrant Agreement. As provided
in the Warrant Agreement, the Warrant Price and the number or kind of shares which may be purchased upon the exercise of the Warrant
evidenced by this Warrant Certificate are, upon the happening of certain events, subject to modification and adjustment.

 

    	 	1	 

     

    

 

This
Warrant Certificate is issued under and in accordance with a Warrant Agreement dated as of February 28, 2018, and is subject to
the terms and provisions contained in the Warrant Agreement, to all of which the Holder of this Warrant Certificate by acceptance
of this Warrant Certificate consents. A copy of the Warrant Agreement may be obtained by the Holder hereof upon written request
to the Company. In the event that pursuant to the Warrant Agreement a warrant agent is appointed and a new warrant agreement entered
into between the Company and such warrant agent, then such new warrant agreement shall constitute the Warrant Agreement for purposes
hereof and this Warrant Certificate shall be deemed to have been issued pursuant to such new warrant agreement.

 

Upon
any partial exercise of the Warrant evidenced by this Warrant Certificate, there shall be issued to the Holder hereof a new Warrant
Certificate in respect of the shares of Common Stock as to which the Warrant evidenced by this Warrant Certificate shall not have
been exercised to the extent provided in the Warrant Agreement. This Warrant Certificate may be exchanged at the office of the
Company (or the warrant agent, if appointed) by surrender of this Warrant Certificate properly endorsed either separately or in
combination with one or more other Warrant Certificates for one or more new Warrant Certificates evidencing the right of the Holder
thereof to purchase the aggregate number of shares as were purchasable on exercise of the Warrants evidenced by the Warrant Certificate
or Certificates exchanged. No fractional shares will be issued upon the exercise of any Warrant, but the Company will pay the
cash value thereof determined as provided in the Warrant Agreement. This Warrant Certificate is transferable at the office of
the Company (or the warrant agent, if appointed) in the manner and subject to the limitations set forth in the Warrant Agreement.

 

The
Holder hereof may be treated by the Company, the warrant agent (if appointed), and all other persons dealing with this Warrant
Certificate as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented hereby,
or to the transfer hereof on the books of the Company, any notice to the contrary notwithstanding, and until such transfer on
such books, the Company (and the warrant agent, if appointed) may treat the Holder hereof as the owner for all purposes.

 

Neither
the Warrant nor this Warrant Certificate entitles any Holder to any of the rights of a stockholder of the Company.

 

    	 	2	 

     

    

 

[This
Warrant Certificate shall not be valid or obligatory for any purpose until it shall have been countersigned by the warrant agent.]*

 

DATED:

 

	 	AGEX THERAPEUTICS, INC.
	 	 
	(Seal)	By:	                       
	 	 	 
	 	Title:
    	 

 

Attest:____________________

[COUNTERSIGNED:

WARRANT
AGENT

 

By:_________________________]*

Authorized
Signature

____________________

 

	*	To
    be part of the Warrant only after the appointment of a warrant agent pursuant to the Warrant Agreement.

 

    	 	3	 

     

    

 

PURCHASE
FORM

 

(To
be executed upon exercise of Warrant)

 

To
AgeX Therapeutics, Inc.:

 

The
undersigned hereby irrevocably elects to exercise the right of purchase represented by the within Warrant Certificate for, and
to purchase thereunder, _______ shares of Common Stock, as provided for therein, and tenders herewith payment of the Warrant Price
in full in the form of a bank wire transfer to the account of the Company or by bank cashier’s check in the amount of $______________.

 

Please
issue a certificate or certificates for such shares of Common Stock in the name of, and pay any cash for any fractional share
to:

 

____________________________________

(Please
Print Name)

 

____________________________________

(Please
Print Address)

 

____________________________________

(Social
Security Number or

Other
Taxpayer Identification Number)

 

____________________________________

(Signature)

 

	NOTE:	The above signature should correspond
    exactly with the name on the face of this Warrant Certificate or with the name of the assignee appearing in the assignment
    form below.

 

And,
if said number of shares shall not be all the shares purchasable under the within Warrant Certificate, a new Warrant Certificate
is to be issued in the name of said undersigned for the balance remaining of the share purchasable thereunder, to the extent provided
in the Warrant Agreement, less any fraction of a share paid in cash.

 

    	 	4	 

     

    

 

ASSIGNMENT

 

(To
be executed only upon assignment of Warrant Certificate)

 

For
value received, _____________ hereby sells, assigns and transfers unto _______________ the within Warrant Certificate, together
with all right, title and interest therein, and does hereby irrevocably constitute and appoint _________________ attorney, to
transfer said Warrant Certificate on the books of the within-named Company, with full power of substitution in the premises.

 

Dated:___________________

________________________________

(Signature)

 

	 	NOTE:
    	The
    above signature should correspond exactly with the name on the face of this Warrant Certificate.

 

 

    	 	5Exhibit 10.1

 

 

 

 

March 29, 2019

 

Michael Ciraolo, J.D., Ph.D.

10 Northfield Lane

Saint James, NY 11780

Via email: Michael.ciraolo@gmail.com

 

		Re:	Employment Offer Letter

 

Dear Michael:

 

On behalf of Neurotrope (“Neurotrope” or the “Company”),
I am pleased to offer you employment with Neurotrope under the terms and conditions set forth in this letter (the “Agreement”).
If you sign and return the Agreement to me, it will become effective as of your first day of employment with the Company, April
1, 2019 (the “Effective Date”). By signing this Agreement, in consideration of your employment, you (“Employee”)
and the Company agree as follows:

 

1.       Position of Employment.
Neurotrope will employ you in the position of General Counsel and Chief Operating Officer of Neurotrope and, in that position,
Employee will report directly to the Chief Executive Officer (“CEO”) of Neurotrope.

 

2.       Term of Employment.
You will be employed by the Company on an “at-will” basis. This means that the Company may terminate Employee’s
employment for any reason, at any time, with or without cause. Similarly, Employee is free to resign at any time, for any reason
or for no reason. Employee’s compensation in the event of termination or resignation shall be in accordance with Section
4 of this Agreement.

 

3.       Compensation
and Benefits.

 

A.       Base
Salary. Employee shall initially be paid a base salary of $335,000 in cash annually by Neurotrope, to be paid in accordance
with Neurotrope’s regular payroll policies but no less frequently than twice per month ("Base Salary"). Employee’s
Base Salary shall be reviewed annually or periodically in accordance with Neurotrope’s normal compensation review cycle,
but any increase above the amounts herein specified shall be in the sole discretion of Neurotrope’s CEO and the Board of
Directors (Compensation Committee) and nothing herein shall be deemed to require any such increase.

 

B.        Annual
Bonuses. Employee shall be eligible to earn an annual bonus (the “Annual Bonus”) targeted at 30% of Employee’s
Base Salary in effect at the time of payment. The Annual Bonus is not guaranteed, with the decision whether to award Employee such
bonus and the amount of such bonus, if any, being in the sole and absolute discretion of Neurotrope’s CEO and the Board of
Directors (Compensation Committee). The Annual Bonus, if any, will be paid when such bonuses are paid to similarly situated employees
of the Company. In order to receive the Annual Bonus, Employee must be employed by Neurotrope on the date of payment of such bonus.

 

    	
 
1185 Avenue of the Americas, 3rd Floor
New York, NY 10036
	
 -1-

 www.neurotrope.com
	
 
 
 

(973) 242.0005

     

    

 

C.       Equity. Subject to the approval of
the Board or the Compensation Committee of the Board, as applicable, at the next meeting of the Board or the Compensation Committee
of the Board following the Effective Date, you will be issued an option to purchase 100,000 shares of the Company’s common
stock (“Options”) pursuant to the Company’s 2017 Equity Incentive Plan (as amended from time to time the “Plan”).
Twenty five percent (25%) of your stock options will vest immediately and the remaining 75 percent (75%) of your stock options
will vest in substantially equal monthly installments (rounded down to the nearest whole number) over a period of two years as
measured from the Effective Date, subject to your continued employment through the vesting date, provided, however, that if a Change
of Control (as such term is defined in the Plan) occurs while you are employed by the Company all Options shall vest upon the Change
of Control. The exercise price per share for the Options will be the per share fair market value of the Company’s common
stock on the date of grant, as determined by the Board in accordance with the Plan. The Options and any additional stock options
will be subject to the terms and conditions of the Company’s form of option agreement and the Plan.

 

D.       Employee
Benefits. Employee shall be eligible to participate in all employee benefit plans, policies, programs, or privileges made available
to employees of Neurotrope generally or to executive officers of Neurotrope. The terms and conditions of Employee's participation
in Neurotrope's employee benefit plans, policies, programs, or privileges shall be governed by the terms and conditions or practices
of each such plan, policy, or program, or privilege, each of which may be terminated or amended at any time in the Company’s
sole discretion.

 

E.        Annual
Vacation. Employee shall be entitled to twenty (20) business days of paid vacation
during each year of this Agreement. Employee may be absent from his employment for vacation at such times as are pre-approved by
the CEO. Unused vacation shall not be carried over into the next year, and any unused vacation shall be forfeited upon termination
for any reason.

 

4.       Termination of
Employment. If the Employee’s employment is terminated for any reason or if the Employee resigns, the Company will pay
to the Employee all accrued but unpaid Base Salary as of the date of termination, and reimbursement for any properly incurred but
unreimbursed business expenses. In addition:

 

A.       Termination
by Neurotrope Without Cause.  If the Company terminates the Employee’s employment without Cause (and other than due to
Employee’s death or because the Employee is no longer able to perform the essential duties of his position, with or without
a reasonable accommodation, as a result of any physical or mental condition), the Company will pay the Employee 1/12th
of his Base Salary for the Severance Period (as defined below).

 

B.       Termination
by Employee for Good Reason. If the Employee resigns for Good Reason, the Company the Company will pay the Employee 1/12th
of his Base Salary for the Severance Period. Any notice of resignation for Good Reason must be given to the Company no later than
thirty (30) days following the initial occurrence of the condition constituting Good Reason, and the last date of employment if
the Company fails to cure the condition shall be the sixty-first day following the Company’s receipt of such written notice.

 

    	
 
1185 Avenue of the Americas, 3rd Floor
New York, NY 10036
	
 -2-

 www.neurotrope.com
	
 
 
 
 
(973) 242.0005

     

    

 

C.       The Employee’s
receipt of the benefits set forth in this Section 4 are conditioned upon the Employee’s executing (and not revoking) no later
than the 60th day following the Employee’s last date of employment a form of separation agreement containing a
general release of claims to be provided by the Company.

 

D.         Definitions:
For purposes of this Section 4:

 

“Cause” means any
of the following actions by Employee: (i) indictment of any felony or any crime involving moral turpitude; (ii) fraud against the
Company or any of its affiliates, or theft of, or maliciously intentional damage to, the property of the Company or any of its
affiliates; (iii) breach of Executive’s fiduciary duties to the Company or any of its affiliates or misconduct as an employee
of the Company that results in economic detriment to the Company or any of its affiliates; (iv) conduct which, in the reasonable
opinion of the Company’s CEO, brings or is likely to bring Employee, the Company or any or any of its affiliates into disrepute;
(v) breach of Company policies, including without limitation risk management policies and procedures, codes of conduct and ethical
standards in the performance of Employee’s duties; (vi) neglect or unreasonable refusal to perform the material duties and
responsibilities assigned to Employee by the CEO or the Board; (vii) performance of Employee’s job responsibilities at a
level below the standards or requirements set by the CEO or the Board; or (viii) breach by Employee of any provision of the Employee
Confidentiality and Inventions Agreement.

 

“Good Reason” means
a termination of employment by Employee for one or more of the following reasons that remains uncured by the Company for a period
of thirty (30) days following the Company’s receipt of written notice from the Employee setting forth the circumstances constituting
Good Reason: (i) a material negative change in Employee’s reporting structure such that Employee no longer reports directly
to the CEO; (ii) a material reduction at any time in Employee’s then current Base Salary; (iii) a
material diminution in the Employee’s authority, duties or responsibilities; or (iv) Company’s insistence that
Employee perform or condone any illegal conduct.

 

“Severance Period”
means (i) if no Change of Control has occurred (A) three (3) months if the termination date is prior to the first anniversary of
the Employee’s start of employment with the Company, (B) six (6) months if the termination date is after first anniversary
of the Employee’s start of employment with the Company but before the second anniversary of such date, or (C) nine (9) months
if the termination date is after the second anniversary of the Employee’s start of employment, and (ii) if a Change of Control
has occurred as of the termination date, twelve (12) months.

 

		5.	General Provisions.

 

A.         
Representations. In making this offer of employment, the Company has relied on Employee’s representations that (a) 
Employee is not subject to any non-competition arrangement or other restrictive covenants that might affect his employment by the
Company as contemplated by this Agreement, (b) Employee shall not disclose to the Company any proprietary or confidential information
belonging to any other party, (c)  Employee is free to accept this offer of employment and to perform the duties contemplated
herein and commensurate with the offered position and (d) Employee’s employment with the Company will not violate or conflict
with any other obligation or arrangement to which Employee is a party. 

 

    	
 
1185 Avenue of the Americas, 3rd Floor
New York, NY 10036
	
 -3-

 www.neurotrope.com
	
 
 
 
 
(973) 242.0005

     

    

 

B.       Notices.
All notices and other communications required or permitted by this Agreement to be delivered to Neurotrope or the Company or Employee
to the other party shall be delivered in writing to the address shown below, either personally, by electronic mail, or by registered,
certified, or express mail, return receipt requested, postage prepaid, to the address for such party specified below or to such
other address as the party may from time to time advise the other party in writing in the same manner as set forth in this Section
5.B., and shall be deemed given and received as of actual personal delivery, on the first business day after the date of delivery
shown on any such electronic mail or facsimile transmission or upon the date or actual receipt shown on any return receipt if registered,
certified, or express mail is used, as the case may be.

Company:

              

Charles Ryan, J.D., Ph.D.

Chief Executive Officer

Neurotrope

1185 Avenue of
the Americas

New York, NY 10036

cryan@ntrpbio.com

 

Employee:

             

Michael Ciraolo, J.D., Ph.D.

10 Northfield Lane

Saint James NY 11780

michael.ciraolo@gmail.com

 

C.   
    Amendments and Termination; Entire Agreement. This Agreement may not be amended or terminated
except by a writing executed by all of the parties hereto. This Agreement, along with the Employee Confidentiality and
Inventions Agreement, constitutes the entire agreement of the Company and Employee relating to the subject matter hereof and
supersedes all prior oral and written understandings and agreements relating to such subject matter.

 

D.       Successors
and Assigns. The rights and obligations of the parties hereunder are not assignable to another person without prior written
consent; provided, however, that Company’s obligations hereunder shall be binding upon their successors and assigns.

 

E.       Severability;
Provisions Subject to Applicable Law. All provisions of this Agreement shall be applicable only to the extent that they do
not violate any applicable law, and are intended to be limited to the extent necessary so that they will not render this Agreement
invalid, illegal or unenforceable under any applicable law. If any provision of this Agreement or any application thereof shall
be held to be invalid, illegal or unenforceable, the validity, legality and enforceability of other provisions of this Agreement
or of any other application of such provision shall in no way be affected thereby.

 

    	
 
1185 Avenue of the Americas, 3rd Floor
New York, NY 10036
	
 -4-

 www.neurotrope.com
	
 
 
 
 
(973) 242.0005

     

    

 

F.       Waiver
of Rights. No waiver by Neurotrope, the Company or Employee of a right or remedy hereunder shall be deemed to be a waiver of
any other right or remedy or of any subsequent right or remedy of the same kind.

 

G.       Definitions;
Headings; Number. A term defined in any part of this Agreement shall have the defined meaning wherever such term is used herein.
The headings contained in this Agreement are for reference purposes only and shall not affect in any manner the meaning or interpretation
of this Agreement. Where appropriate to the context of this Agreement, use of the singular shall be deemed also to refer to the
plural, and use of the plural to the singular.

 

H.       Counterparts.
This Agreement may be executed in separate counterparts and by facsimile, electronic, or pdf, each of which shall be deemed an
original but both of which taken together shall constitute but one and the same instrument.

 

I.      
 Governing Laws; Forum. This Agreement shall be governed by, construed, and enforced in accordance with the laws
of the State of New York. The parties hereto further agree that any action brought to enforce any right or obligation under
this Agreement shall be subject to the exclusive jurisdiction of the state or federal courts of the State of New York.

 

J.       Section
409A.

 

i.                 
For purposes of this Agreement, “Section 409A” means Section 409A of the Internal Revenue Code of 1986, as amended
(the “Code”), and the Treasury Regulations promulgated thereunder (and such other Treasury or Internal Revenue Service
guidance) as in effect from time to time.

 

ii.                 
Notwithstanding anything in this Agreement to the contrary, the following special rule shall apply, if and to the extent required
by Section 409A, in the event that (a) the Employee is deemed to be a “specified employee” within the meaning of Section
409A(a)(2)(B)(i), (b) amounts or benefits under this Agreement or any other program, plan or arrangement of the Company or a controlled
group affiliate thereof are due or payable on account of the Employee’s “separation from service” within the
meaning of Treasury Regulations Section 1.409A-1(h) and (c) the Employee is employed by a public company or a controlled group
affiliate thereof: no payments hereunder that are “deferred compensation” subject to Section 409A shall be made to
the Employee prior to the date that is six (6) months after the date of the Employee’s separation from service or, if earlier,
the Employee’s date of death; following any applicable six (6) month delay, all such delayed payments will be paid in a single
lump sum on the earliest permissible payment date.

 

    	
 
1185 Avenue of the Americas, 3rd Floor
New York, NY 10036
	
 -5-

 www.neurotrope.com
	
 
 
 
 
(973) 242.0005

     

    

 

 

iii.                 
Each payment made under this Agreement (including each separate installment payment in the case of a series of installment payments)
shall be deemed to be a separate payment for purposes of Section 409A. Amounts payable under this Agreement shall be deemed not
to be a “deferral of compensation” subject to Section 409A to the extent provided in the exceptions in Treasury Regulation
 §§ 1.409A-1(b)(4) (“short-term deferrals”) and (b)(9) (“separation pay plans,” including the
exception under subparagraph (iii)) and other applicable provisions of Section 409A. For purposes of this Agreement, with respect
to payments of any amounts that are considered to be “deferred compensation” subject to Section 409A, references to
 “termination of employment”, “termination”, or words and phrases of similar import, shall be deemed to
refer to the Employee’s “separation from service” as defined in Section 409A, and shall be interpreted and applied
in a manner that is consistent with the requirements of Section 409A.

 

IN WITNESS WHEREOF, Neurotrope, the Company and Employee have
executed and delivered this Agreement as of the date first written above.

 

	NEUROTROPE	 	 	 
	 	 	 	 
	/s/ Charles Ryan, J.D., Ph.D.	 	Date: March
    29, 2019 	 
	Charles Ryan, J.D., Ph.D.	 	 	 
	CEO, Neurotrope	 	 	 
	 	 	 	 
	 	 	 	 
	Employee	 	 	 
	 	 	 	 
	/s/ Michael Ciraolo, J.D., Ph.D.	 	Date: March
    29, 2019	 
	Michael Ciraolo, J.D., Ph.D.	 	 	 

 

 

    	
 
1185 Avenue of the Americas, 3rd Floor
New York, NY 10036
	
 -6-

 www.neurotrope.com
	
 
 
 
 
(973) 242.0005

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]